Abstract: Antigens encoded by MAGE genes are of particular interest for cancer immunotherapy because of their strict tumoral specificity and because they are shared by many tumors. Antigenic peptide EVDPIGHLY encoded by MAGE-3 and known to be presented by HLA-A*0101 is currently being used in therapeutic vaccination trials. We report here that a cytolytic Tlymphocyte (CTL) clone, which is restricted by HLA-B*3501, recognizes the same peptide and, importantly, lyses HLA-B*3501 tumor cells expressing MAGE-3. These results infer that the current clinical use of peptide EVDPIGHLY can now be extended to HLA-B*3501 patients. 
Gene MAGE-3 is frequently expressed in metastatic melanomas (76%) and in carcinomas of the esophagus (47%), the head and neck (49%), the lung (47%) and the bladder (36%) (6) (F. Brasseur, unpublished results). CTL isolated from two melanoma patients in mixed lymphocyte-tumor cell cultures have been found to recognize MAGE-3 peptides presented by HLA-A*0101 or B37 (1, 7). To identify additional CTL epitopes, synthetic peptides have been used to stimulate T cells from blood donors without cancer and this has led to the identification of MAGE-3 epitopes presented by HLA-A*0201, A24, B*4402 and B*4403 (8) (9) (10) (11) . We are using now another ''reverse immunology'' strategy: dendritic cells transduced with gene MAGE-3 are used as stimulator cells for autologous T lymphocytes obtained from non-cancerous blood donors (12, 13) . This has already resulted in the identification of several MAGE epitopes (12) (13) (14) (15) . We describe here the identification of a new MAGE-3 epitope, using the same method.
Material and methods

Cell lines, media and reagents
The Epstein-Barr virus (EBV)-transformed B (EBV-B) cell lines
were derived from peripheral blood lymphocytes (PBLs) of hemochromatosis blood donor LB 1841 with 1 mg/ml of Cyclosporin A (Sandoz, Basel, Switzerland) and 20% of supernatant of EBVtransformed B95-8 cells using standard techniques. The EBV-B cell lines and the melanoma cell lines were cultured in Iscove's modified Dulbecco medium (IMDM) (Gibco Brl, Gaithersburg, MD, USA) supplemented with 10% foetal calf serum (FCS) (Gibco Brl), 0.24 mM L-asparagine, 0.55 mM L-arginine, 1.5 mM L-glutamine (AAG), 100 U/ml penicillin and 100 mg/ml streptomycin. 293-EBNA cells (Invitrogen, Groningen, Netherlands) were derived from a human embryonal kidney cell line (ATCC: CRL 1573), which were transformed with an adenovirus type V. Cells were typed HLA-A3, B7, and Cw7. They were also tested positive for HLA-A, -B, and -C expression with mAb W6/32 (16). They were maintained in DMEM medium (Gibco Brl) supplemented with 10% FCS, 100 U/ml penicillin and 100 mg/ml streptomycin. Human recombinant interleukin (IL)-2 was purchased from Eurocetus (Amsterdam, Netherlands). One unit/ml of IL-2 is the concentration needed to obtain half-maximal proliferation of mouse CTLL-2 cells. IL-7 was purchased from Genzyme (Cambridge, MA, USA), GM-CSF from Schering Plough (Brinny, Ireland). Human recombinant IL-4, IL-6, and IL-12 were produced in our laboratory. One unit/ml of IL-6 is the concentration needed to obtain half-maximal proliferation of mouse 7TD1 cells (17). ml of Lipofectamine (Gibco Brl). One day after transfection, 3,000 CTL 41 were added to the transfected cells in a total volume of 100 ml of complete IMDM supplemented with 25 U/ml of IL-2. Interferon (IFN)-g production was estimated after overnight co-culture by ELISA.
Peptides recognition assays
Peptides were synthesized on solid phase using F-moc for transient NH2-terminal protection and were characterized using mass spectrometry. All peptides were Ͼ80% pure, as indicated by analytical high-power liquid chromatography (HPLC). Lyophilized peptides were dissolved at 2 mg/ml in DMSO/acetic acid 10 mM, and stored at ª20 aeC. Target cells were labelled with Na( 
Results and discussion
Monocyte-derived dendritic cells of blood donor LB 1841 were infected with a canarypox virus, ALVAC (22) Cr-labeled for 1 h and incubated with the autologous CTL at the indicated effector-to-target ratios. Chromium release was measured after 4 h. Fig. 2 . A MAGE-3 epitope presented by HLA-B*3501. 293-EBNA cells, which derived from a human embryonal kidney cell line, were transiently transfected with a MAGE-3 cDNA and each of the cDNAs coding for putative HLA-presenting molecules. The cDNAs were inserted in expression vector pcDNAI/Amp or pcDNA3. Transfections were performed in microwells with 18,000 293-EBNA cells, 50 ng of the HLA cDNA and 50 ng of the MAGE-3 cDNA in the presence of 1 ml of Lipofectamine. One day after transfection, 3,000 CTL 41 were added to the transfected cells. IFN-g production was estimated after overnight co-culture by ELISA.
was that EBV-B cells infected with ALVAC are poor targets for chromium-release assays. The second reason for using a different viral vector for the lytic assay is to exclude the responder T cells directed against viral epitopes. We used as negative controls EBV- Cr-labeled and incubated for 4 h with CTL clone 41 at the indicated effector-to-target ratios. Cell lines were either untreated (S) or pretreated with 100 U/ml IFN-g for 48 h (P). g (Fig. 2) . The cells transfected with MAGE-3 and HLA-B*3503, another B35 allele, were not recognized. (23). But peptide DPIGHLYIF, which contains these potential anchor residues, proved incapable of sensitizing EBV-B cells to lysis by CTL 41 (Fig. 3) . In contrast, peptides MEVDPIGHLY and EVDPIGHLY scored positive in this cytotoxicity assay and both produced half-maximal lysis of autologous EBV-B target cells at ∂0.05 nM. This is lower than the previously identified MAGE antigenic peptides, for which values ranging from 0.1 to 25 nM were observed (12, 14, 24, 25) fectly lysed, but only after 48 h of incubation with IFN-g, which is known to upregulate the expression of HLA molecules (Fig. 4) . LB1622-MEL cells, which express allele B*3528 and MAGE-3, also stimulated CTL 41, and were lysed slightly by CTL 41 even without IFN-g treatment (Fig. 4) . 15, 24) . In an ongoing clinical trial, melanoma patients have been injected with a canarypox virus, ALVAC, encoding a sequence containing MAGE-1 peptide EADPTGHSY and MAGE-3 peptide EVDPIGHLY (Fig. 5) . We infected B*3501 dendritic cells with this recombinant poxvirus. The infected cells stimulated efficiently CTL 41 to produce IFN-g (Fig. 6 ).
Thus, with those presented by HLA-A1, A2, A24, B35, B37, and B44, MAGE-3 antigenic peptides are now available for 45 to 90% of Caucasians. These percentages are based on the ranges of frequency for the different HLA presenting molecules (26), but do not take into account the fact that the antigenic peptides might be presented only by a subset of these HLA alleles. These results suggest also that most, if not all HLA alleles can present at least one MAGE-3 peptide. HLA typing will therefore not be necessary as an eligibility criterion to immunize patients with a MAGE-3 protein or viral vectors containing the entire MAGE-3 coding sequence. Our results infer that the clinical use of peptide EVDPIGHLY and ALVAC canarypox virus encoding this peptide, presently restricted to HLA-A1 patients, can now be extended to HLA-B*3501 patients. Another consequence is that the monitoring of the cellular immune response of HLA-A1 and B35 patients vaccinated with this peptide has now to include the search for B35-restricted CTL in addition to A1-restricted ones.
